Chemiphar Revises Forecasts Up Following Q3 Performance
Japanese Generics Firm Finally Shaking Off Impact Of NHI Revision And COVID-19
Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.
You may also be interested in...
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.
IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.